DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Molecular Markers in Thyroid Cancer

Completed

Conditions: Thyroid Cancer

First Posted Date: 2008-01-21

Last Posted Date: 2014-12-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 847

Registration Number: NCT00598364

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Strength Training for Older Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Neoplasm
Osteoporosis, Postmenopausal

Interventions: Behavioral: Resistance Exercise
Behavioral: Flexibility Training

First Posted Date: 2008-01-11

Last Posted Date: 2015-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 106

Registration Number: NCT00591747

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

First Posted Date: 2007-08-15

Last Posted Date: 2012-07-24

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00516542

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Docetaxel in Treating Patients With Relapsed Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

First Posted Date: 2007-06-05

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00482274

Locations: 🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

First Posted Date: 2007-04-13

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00459810

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

First Posted Date: 2007-01-29

Last Posted Date: 2011-09-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT00428077

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: sunitinib malate
Procedure: biopsy

First Posted Date: 2007-01-23

Last Posted Date: 2017-05-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00425386

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Salem Hospital, Salem, Oregon, United States

and more 1 locations

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: Campath
Drug: Fludarabine
Radiation: Total Body Irradiation (TBI)
Other: T-Cell Deplete

First Posted Date: 2006-12-28

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00416884

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase 1

Withdrawn

Conditions: Drug/Agent Toxicity by Tissue/Organ
Cognitive/Functional Effects
Brain and Central Nervous System Tumors
Breast Cancer
Psychosocial Effects of Cancer and Its Treatment

Interventions: Drug: carboplatin
Biological: trastuzumab
Drug: methotrexate
Drug: sodium thiosulfate

First Posted Date: 2006-11-09

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT00397501

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Phase 2

Completed

Conditions: Colorectal Cancer
Nausea and Vomiting

Interventions: Drug: aprepitant
Drug: dexamethasone
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: palonosetron hydrochloride
Procedure: quality-of-life assessment

First Posted Date: 2006-09-28

Last Posted Date: 2017-06-12

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00381862

Locations: 🇺🇸
St. Josephs/Cander Hospital, Savannah, Georgia, United States
🇺🇸
Kaiser Permanente, Hilo, Hawaii, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy